登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《BioRxiv，3月2日，Kallikrein 13: a new player in coronaviral infections.》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-03-03

  • Kallikrein 13: a new player in coronaviral infections.

    Aleksandra Milewska, Katherine Falkowski, Magdalena Kalinska, Ewa Bielecka, Antonina Naskalska, Pawel Mak, Adam Lesner, Marek Ochman, Maciej Urlik, Jan Potempa, Tomasz Kantyka, Krzysztof Pyrc

    doi: https://doi.org/10.1101/2020.03.01.971499

    Abstract

    Human coronavirus HKU1 (HCoV-HKU1) is associated with respiratory disease and is prevalent worldwide, but in vitro model for virus replication is lacking. Interaction between the coronaviral spike (S) protein and its receptor is the major determinant of virus tissue and host specificity, but virus entry is a complex process requiring a concerted action of multiple cellular elements. Here, we show that KLK13 is required for the infection of the human respiratory epithelium and is sufficient to mediate the entry of HCoV-HKU1 to non-permissive RD cells. We also demonstrated HCoV-HKU1 S protein cleavage by KLK13 in the S1/S2 region, proving that KLK13 is the priming enzyme for this virus. Summarizing, we show for the first time that protease distribution and specificity predetermines the tissue and cell specificity of the virus and may also regulate interspecies transmission. It is of importance that presented data may be relevant for the emerging coronaviruses, including SARS-CoV-2, and may help to understand the differences in their zoonotic potential.

    *注，本文为预印本论文手稿，是未经同行评审的初步报告，其观点仅供科研同行交流，并不是结论性内容，请使用者谨慎使用.

  • 原文来源：https://www.biorxiv.org/content/10.1101/2020.03.01.971499v1
15浏览量
原文链接
相关报告

  • 《Science，11月24日，Kallikrein 13 serves as a priming protease during infection by the human coronavirus HKU1》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-12-22
    • Kallikrein 13 serves as a priming protease during infection by the human coronavirus HKU1 View ORCID ProfileAleksandra Milewska1,2, View ORCID ProfileKatherine Falkowski2, View ORCID ProfileMagdalena Kulczycka3, Ewa Bielecka3, View ORCID ProfileAntonina Naskalska1,... Science Signaling 24 Nov 2020: Vol. 13, Issue 659, eaba9902 DOI: 10.1126/scisignal.aba9902 Abstract Human coronavirus HKU1 (HCoV-HKU1) is associated with respiratory disease and is prevalent worldwide, but an in vitro model for viral replication is lacking. An interaction between the coronaviral spike (S) protein and its receptor is the primary determinant of tissue and host specificity; however, viral entry is a complex process requiring the concerted action of multiple cellular elements. Here, we found that the protease kallikrein 13 (KLK13) was required for the infection of human respiratory epithelial cells and was sufficient to mediate the entry of HCoV-HKU1 into nonpermissive RD cells. We also demonstrated the cleavage of the HCoV-HKU1 S protein by KLK13 in the S1/S2 region, suggesting that KLK13 is the priming enzyme for this virus. Together, these data suggest that protease distribution and specificity determine the tissue and cell specificity of the virus and may also regulate interspecies transmission.
    20浏览量
    原文链接

  • 《BioRxiv，3月27日，FDA approved drugs with broad anti-coronaviral activity inhibit SARS-CoV-2 in vitro》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-03-30
    • FDA approved drugs with broad anti-coronaviral activity inhibit SARS-CoV-2 in vitro Stuart Weston, Rob Haupt, James Logue, Krystal Matthews, Matthew Frieman doi: https://doi.org/10.1101/2020.03.25.008482 Abstract SARS-CoV-2 emerged in China at the end of 2019 and has rapidly become a pandemic with over 400,000 recorded COVID-19 cases and greater than 19,000 recorded deaths by March 24th, 2020 (www.WHO.org). There are no FDA approved antivirals or vaccines for any coronavirus, including SARS-CoV-2. Current treatments for COVID-19 are limited to supportive therapies and off-label use of FDA approved drugs. Rapid development and human testing of potential antivirals is greatly needed. A potentially quicker way to test compounds with antiviral activity is through drug re-purposing. Numerous drugs are already approved for use in humans and subsequently there is a good understanding of their safety profiles and potential side effects, making them easier to test in COVID-19 patients. Here, we present data on 20 FDA approved drugs tested for antiviral activity against SARS-CoV-2 that we have previously found to inhibit SARS-CoV and MERS-CoV. *注，本文为预印本论文手稿，是未经同行评审的初步报告，其观点仅供科研同行交流，并不是结论性内容，请使用者谨慎使用.
    136浏览量
    原文链接